A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome)

Mantu Bhaumik(Albert Einstein College of Medicine), Vivienne Muller(Albert Einstein College of Medicine), Tina Rozaklis(Albert Einstein College of Medicine), J. Linda(Albert Einstein College of Medicine), Kostantin Dobrenis(Albert Einstein College of Medicine), Roby P. Bhattacharyya(Albert Einstein College of Medicine), Sarah Wurzelmann(Albert Einstein College of Medicine), P. Finamore(Albert Einstein College of Medicine), John J. Hopwood(Women's and Children's Hospital), Steven U. Walkley(Albert Einstein College of Medicine), Pamela Stanley(Albert Einstein College of Medicine)
Glycobiology
December 1, 1999
Cited by 187Open Access
Full Text

Abstract

Mucopolysaccharidosis type III A (MPS III A, Sanfilippo syndrome) is a rare, autosomal recessive, lysosomal storage disease characterized by accumulation of heparan sulfate secondary to defective function of the lysosomal enzyme heparan N- sulfatase (sulfamidase). Here we describe a spontaneous mouse mutant that replicates many of the features found in MPS III A in children. Brain sections revealed neurons with distended lysosomes filled with membranous and floccular materials with some having a classical zebra body morphology. Storage materials were also present in lysosomes of cells of many other tissues, and these often stained positively with periodic-acid Schiff reagent. Affected mice usually died at 7-10 months of age exhibiting a distended bladder and hepatosplenomegaly. Heparan sulfate isolated from urine and brain had nonreducing end glucosamine- N -sulfate residues that were digested with recombinant human sulfamidase. Enzyme assays of liver and brain extracts revealed a dramatic reduction in sulfamidase activity. Other lysosomal hydrolases that degrade heparan sulfate or other glycans and glycosaminoglycans were either normal, or were somewhat increased in specific activity. The MPS III A mouse provides an excellent model for evaluating pathogenic mechanisms of disease and for testing treatment strategies, including enzyme or cell replacement and gene therapy.


Related Papers

No related papers found

Powered by citation graph analysis